

## QIBA CT Volumetry Biomarker Ctte (BC) Call

03 May 2018 at 11 AM CT, Thursday

Call Summary

### In attendance:

Ehsan Samei, PhD (Co-Chair)

Jenifer Siegelman, MD, MPH (Co-Chair)

Hubert Beaumont, PhD

Heang-Ping Chan, PhD

Marios Gavrielides, PhD

David Gustafson, PhD

Lubomir Hadjiiski, PhD

Phillip Hoelzer, PhD

Edward Jackson, PhD

Hyun Grace Kim, PhD

Yongguang Liang, PhD

Nancy Obuchowski, PhD

Kevin O'Donnell, MASC

Fabien Ricard, MD, MS

Ying Tang, PhD

### RSNA:

Fiona Miller

Joe Koudelik

Julie Lisiecki

**Moderator:** Dr. Samei

### Vol CT Advanced Disease [Profile Technical Confirmation Feedback](#) Efforts:

- Dr. Samei reviewed remaining outstanding to-do items
- Mr. O'Donnell noted that cleanup of the Profile is nearly complete
- Some misalignments of test data were sorted out with the help of Drs. Petrick and Obuchowski
  - Updates included adjustments to data, equations, instructions
- Dr. Petrick is finalizing last changes to his data, which will be posted to the [QIDW](#)
  - A colleague of Dr. Petrick's has volunteered to test the Profile to check for technically confirmed readiness
- Mr. O'Donnell to email the current marked-up version of the Profile to Drs. Siegelman and Gavrielides, with cc to Drs. Samei and Jarecha
- Prior to May 10<sup>th</sup>, Drs. Gavrielides and Siegelman have volunteered to make a line-by-line review of the Profile
- Once all changes are finalized and a clean copy is ready for posting and distribution, an e-ballot will be distributed to eligible BC voting members on May 10<sup>th</sup>
- Two weeks will be allotted for the vote to provide adequate review time
- Dr. Siegelman moved; seconded by Dr. Samei, to vote on publishing the Profile to the Technically Confirmed stage. The motion was approved and confirmed by Mr. O'Donnell

### Voting:

- A majority vote is needed for the Profile to be considered published as technically confirmed
- After voting, negative comments will be discussed as the Profile moves forward
- Any minor issues (typos, minor corrections) can be summarized in a table or log and forwarded to BC members

### Next steps:

- The committee to start thinking about the logistics of moving the current Profile toward the claim confirmed stage and beyond ... to patient care
- Would need clinical trial data from patients with actual lesions documented, not only virtual
- Scan and re-scan data needed
- Consideration of how to measure repeatability within subjects in the field would need to be determined; Dr. Obuchowski offered statistical guidance

### New Directions for the CT Volumetry BC:

- Dr. Samei discussed the co-chairs shared vision for the future of the biomarker committee, which states, *"We are in the variability reduction business for CT lesions to enable better clinical outcomes."*
- This document with other ideas under consideration has been circulated to BC members for review by the next call on May 24<sup>th</sup>
- Feedback is welcome and any comments will be collated by RSNA Staff: [jlisiecki@rsna.org](mailto:jlisiecki@rsna.org)
- BC members are asked to consider what the highest priority should be and what actions must be undertaken to tackle that priority
- Defining what the measurand would be for a new texture (morphology) Profile is needed; Dr. Samei offered to draft a proposal for BC review

**Next Call:** Thursday, May 24<sup>th</sup> at 11:30 am CT